Pfizer and BioNTech said on Thursday that they have begun evaluating their COVID-19 vaccine in children ages 6 months to 11 years both in the US and Europe. The trial will enroll an estimated 4,644 children and results could be available by the second half of this year.
Pfizer, BioNTech launch COVID-19 vaccine trial for kids
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.